PCSK9 and familial hypercholesterolemia: Among such agents, inclisiran, the first-in-class siRNA against PCSK9, has been recently approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with diet and maximally tolerated statin treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or ASCVD who require additional LDL-C lowering [14,15].